Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

AMG 487

Catalog No: tcsc2662

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
473719-41-4

Formula:
$C_{32}H_{28}F_3N_5O_4$

Pathway:
GPCR/G Protein;Immunology/Inflammation

Target:
CXCR;CXCR

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 41 mg/mL (67.93 mM)

Observed Molecular Weight:
603.59

Product Description

AMG 487 is an antagonist of the chemokine receptor **CXCR3**, which inhibits binding of ^{125}I-IP-10 and ^{125}I-ITAC to CXCR3 with **IC_{50}**

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

values of 8.0 and 8.2 nM, respectively.

IC50 & Target: IC50: 8.0 nM (^{125}I-IP-10 binding to CXCR3), 8.2 nM (^{125}I-ITAC binding to CXCR3)

In Vitro: AMG 487 inhibits CXCR3-mediated cell migration by the three CXCR3 chemokines (IP-10 IC_{50}=8 nM, ITAC IC_{50}=15 nM, and MIG IC_{50}=36 nM). Furthermore, AMG 487 inhibits calcium mobilization in response to ITAC (IC_{50}=5 nM)[1]. AMG487 (1 μM) develops into fewer lung metastases, and the lungs are significantly smaller than vehicle-treated lungs[2]. AMG487 abrogates proliferation/survival of C26 tumour cells[3].

In Vivo: AMG 487 (0.03-10 mg/kg, s.c.) exhibits significant reduction in cellular infiltration into the lungs in a dose dependent manner [1]. AMG487 (5 mg/kg, s.c., twice daily) develops fewer metastases than that in vehicle-treated mice[2]. AMG487 (5 mg/kg, s.c.)-treated mice exhibits fewer pulmonary nodules than the control mice in both the models. AMG487 reduces the tumour volume[3].